Burosumab-Twza Injection (Crysvita®)

Burosumab (Crysvita) is covered only for the FDA‑approved non‑oncology indication of X‑linked hypophosphatemia (XLH) and is excluded for other indications. Coverage requires prescription by or consultation with an endocrinologist or nephrologist, baseline pre‑treatment labs showing low serum phosphorus plus either low TmP/GFR or a PHEX mutation (adults also must have XLH signs/symptoms and a prior trial of oral phosphate with calcitriol or documented contraindication), adherence to dosing/frequency limits (adults ≤90 mg no more often than every 4 weeks; pediatrics ≤90 mg no more often than every 2 weeks), 12‑month approvals, and reauthorization only with documented clinical benefit.

"Treatment of X-linked hypophosphatemia (XLH) — Crysvita is indicated for the treatment of XLH (FDA-approved non-oncology indication)."

Sign up to see full coverage criteria, indications, and limitations.